As with most common diseases of the developed world, aging is the major risk factor for developing cancer. Most of the half-dozen hallmarks of precancer that were published last week by investigators from Vanderbilt University and the Fred Hutchinson Cancer Research Center are also hallmarks of aging.
Unfortunately, scientists reported at the American Association for Cancer Research’s (AACR) 2024 annual meeting this week that accelerated aging is increasing, and may be driving an increase in early-onset cancers.
New and updated clinical data presented by biopharma firms at the AACR-NCI-EORTC Conference on Molecular Targets and Cancer Therapeutics
, including: Aprea, Aulos, Avistone, Beyond Cancer, Black Diamond, Cogent, Omega, Ose, Puma, Revolution, Verastem.
New and updated clinical data presented by biopharma firms at the American Association for Cancer Research annual meeting, including: Innovent, Primmune.
New and updated clinical data presented by biopharma firms at the American Association for Cancer Research annual meeting, including: Beigene, Cellular Invlos, Karyopharm, Kinnate, Mapkure, Mendus, Mink, Nouscom, Relay, Repare, Scancell, Sonnet, Springworks, Transgene, Triumvira.
Immuneering Corp.’s positive pharmacokinetic, pharmacodynamic and safety phase I data with universal RAS inhibitor IMM-1-104 let the company move up the timeline for a recommended phase II dose from previous guidance of mid-2024 to early next year.
New and updated clinical data presented by biopharma firms at the American Association for Cancer Research annual meeting, including: Abclon, Allogene, Avistone, Bold, Cantargia, Convergent, Erasca, Evaxion, Exuma, Imcheck, Immunocore, Innovent, Merck, Moderna.
New and updated clinical data presented by biopharma firms at the American Association for Cancer Research annual meeting, including: 23andme, Affimed, Astrazeneca, Genentech, Harbour Biomed, Humanigen, Immune-Onc, Innovent, Mina, Morphosys, Pieris, Quanta, Renovorx, Tempest.
Combining the personalized cancer vaccine mRNA-4157 (V-940, Moderna Inc.) with Keytruda (pembrolizumab, Merck & Co. Inc.) significantly extended recurrence-free survival in patients with stage III/IV resected high-risk melanoma in the randomized phase II KEYNOTE-942/mRNA-4157-P201 trial. Compared to Keytruda alone, adding the vaccine cut the risk of recurrence or death by 44% 18 months after treatment, lead investigator Jeffrey Weber reported at the opening clinical trials plenary of the 2023 annual meeting of the American Association for Cancer Research (AACR).
Solid tumors have been a tougher nut to crack for CAR T cells than B-cell cancers, for two main reasons. Solid tumors have an inhibitors microenvironment that has made it difficult to get durable responses. And identifying antigens as specific as the B-cell markers CD19 and CD22 has been challenging, leading to problems with on-target, off-tumor toxicity.
New and updated preclinical and clinical data presented by biopharma firms at the American Association for Cancer Research annual meeting, including: Akeso, Ascentage, Celsion, Foghorn, Onconano.
RSS
